BeOne Medicines COO gets new equity grants, sells ADS

BeOne Medicines President and COO Wu Xiaobin reported new equity awards and a small tax-related sale.

Rhea-AI Filing Summary

BeOne Medicines President and COO Wu Xiaobin reported new equity awards and a small tax-related sale. He received 118,625 Ordinary Shares through a restricted share unit grant and 229,775 share options with a $20.81 exercise price, both as compensation.

He also sold 626 American Depositary Shares at a weighted average price of $261.2017 per ADS to satisfy mandatory tax withholding tied to earlier restricted share unit vesting. After these awards, he directly holds 1,308,161 Ordinary Shares and 229,775 share options, and indirectly 4,000 ADS held by his wife.

Insights

Equity compensation and insider-transactions analyst

Comp-heavy Form 4: large new grants, small tax-driven sale.

The filing shows Wu Xiaobin, President and COO of BeOne Medicines Ltd., receiving 118,625 Ordinary Shares via restricted share units and 229,775 options with a $20.81 exercise price. These are compensation grants that increase his long-term equity exposure.

The 626 American Depositary Shares sold at a weighted average $261.2017 per ADS were executed under a mandatory tax-withholding provision, according to the footnotes. This indicates the sale is mechanistic tax settlement, not a discretionary reduction in ownership. After these transactions, he holds 1,308,161 Ordinary Shares, 229,775 options, and 4,000 indirectly owned ADS, suggesting the overall activity is routine and primarily compensation-related.

Insider Trade Summary

Net Seller: 626 shares

Net Sell 5 txns

Insider Wu Xiaobin

Role President and COO

Sold 626 shs ($164K)

Type	Security	Shares	Price	Value
Grant/Award	Share Option (Right to Buy)	229,775	$0.00	$0.00
Grant/Award	Ordinary Shares	118,625	$0.00	$0.00
Sale	American Depositary Shares	626	$261.2017	$164K
holding	American Depositary Shares	--	--	--
holding	American Depositary Shares	--	--	--

Holdings After Transaction: Share Option (Right to Buy) — 229,775 contracts (Direct); Ordinary Shares — 1,308,161 shares (Direct); American Depositary Shares — 12,365 shares (Direct); American Depositary Shares — 4,000 shares (Indirect, By Wife)

Footnotes (6)

1. F1. Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.
2. F2. Each American Depositary Share represents 13 Ordinary Shares.
3. F3. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.19 to $261.29, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
5. F5. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
6. F6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Key Figures

ADS sold for tax withholding: 626 American Depositary Shares ADS weighted average sale price: $261.2017 per ADS RSU Ordinary Shares granted: 118,625 Ordinary Shares +5 more

8 metrics

ADS sold for tax withholding 626 American Depositary Shares Open-market sale to satisfy tax withholding

ADS weighted average sale price $261.2017 per ADS Sale price range $261.19–$261.29

RSU Ordinary Shares granted 118,625 Ordinary Shares Restricted share unit award on June 11, 2026 vesting over four years

Share options granted 229,775 options Options on Ordinary Shares granted June 11, 2026

Option exercise price $20.81 per share Exercise price for 229,775 share options

Ordinary Shares held after grant 1,308,161 Ordinary Shares Direct holdings following RSU award

ADS to Ordinary Share ratio 1 ADS : 13 Ordinary Shares Conversion ratio for American Depositary Shares

Indirect ADS holdings by spouse 4,000 American Depositary Shares Indirect ownership through wife

Key Terms

restricted share units, American Depositary Shares, mandatory tax withholding, weighted average price, +2 more

6 terms

restricted share units financial

"Represents securities underlying restricted share units. 1/4th of the securities will vest..."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

American Depositary Shares financial

"Each American Depositary Share represents 13 Ordinary Shares."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

mandatory tax withholding financial

"The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement..."

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Share Option (Right to Buy) financial

"Share Option (Right to Buy)"

accelerated vesting financial

"Unvested securities are subject to accelerated vesting upon certain termination events."

A contract feature that makes stock awards, options, or restricted shares become owned or exercisable earlier than the original schedule. It shortens or cancels the waiting period so recipients can sell, transfer, or exercise their equity sooner — think of a timed lock that is unlocked ahead of schedule. It matters to investors because it changes when shares enter the market, who controls them, and how much dilution or ownership concentration happens.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did BeOne Medicines (ONC) report for Wu Xiaobin?

BeOne Medicines reported that President and COO Wu Xiaobin received 118,625 Ordinary Shares via a restricted share unit grant and 229,775 share options, and sold 626 American Depositary Shares to cover tax withholding obligations related to previously granted restricted share units.

How many shares did Wu Xiaobin acquire in the latest BeOne Medicines Form 4?

Wu Xiaobin acquired 118,625 Ordinary Shares through a restricted share unit award and 229,775 share options with a $20.81 exercise price. These compensation awards significantly increase his potential equity exposure to BeOne Medicines over time, subject to multi-year vesting schedules and continued service.

Why did Wu Xiaobin sell 626 American Depositary Shares of BeOne Medicines (ONC)?

The 626 American Depositary Shares were sold under a mandatory tax withholding provision in his restricted share unit award agreement. The sale was executed to satisfy tax obligations triggered by vesting, rather than a discretionary portfolio decision to reduce his economic exposure to the company.

At what price were BeOne Medicines ADS sold in Wu Xiaobin’s Form 4 filing?

The 626 American Depositary Shares were sold at a weighted average price of $261.2017 per ADS, with individual trades ranging from $261.19 to $261.29. The filing notes that full trade‑level price details are available from the company or the reporting person upon request.

What are Wu Xiaobin’s BeOne Medicines holdings after these transactions?

Following these transactions, Wu Xiaobin directly holds 1,308,161 Ordinary Shares and 229,775 share options. He also indirectly owns 4,000 American Depositary Shares through his wife. These positions come with multi‑year vesting schedules and potential accelerated vesting under certain termination events.

How do the new BeOne Medicines equity awards to Wu Xiaobin vest?

The new restricted share units representing 118,625 Ordinary Shares vest in four annual installments starting June 11, 2026. The 229,775 share options vest 25% on the first anniversary of June 11, 2026, with the remainder vesting in 36 equal monthly installments, all subject to continued service and certain acceleration provisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 05:55 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wu Xiaobin

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL 4051

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	06/11/2026		A		118,625	A	$0	1,308,161	D
American Depositary Shares(2)								12,365	D
American Depositary Shares(2)								4,000	I	By Wife
American Depositary Shares(2)	06/11/2026		S(3)		626	D	$261.2017(4)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	$20.81(5)	06/11/2026		A		229,775(5)		(6)	06/10/2036	Ordinary Shares	229,775	$0	229,775	D

Explanation of Responses:

1. Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 11, 2026, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

2. Each American Depositary Share represents 13 Ordinary Shares.

3. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 10, 2025, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.19 to $261.29, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

5. The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.

6. These securities vest over a four-year period as follows: 25% on the first anniversary of June 11, 2026 with the remaining shares vesting in 36 equal successive monthly installments thereafter, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)